"Electro-clinical Syndromes" with onset in Paediatric Age. the highlights of the clinical-EEG, genetic and therapeutic advances by Parisi, Pasquale et al.
REVIEW Open Access
“Electro-clinical Syndromes” with onset in
Paediatric Age: the highlights of the clinical-EEG,
genetic and therapeutic advances
Pasquale Parisi1*, Alberto Verrotti2, Maria Chiara Paolino1, Rosa Castaldo1, Filomena Ianniello1, Alessandro Ferretti1,
Francesco Chiarelli2 and Maria Pia Villa1
Abstract
The genetic causes underlying epilepsy remain largely unknown, and the impact of available genetic data on the
nosology of epilepsy is still limited. Thus, at present, classification of epileptic disorders should be mainly based on
electroclinical features. Electro-clinical syndrome is a term used to identify a group of clinical entities showing a
cluster of electro-clinical characteristics, with signs and symptoms that together define a distinctive, recognizable,
clinical disorder. These often become the focus of treatment trials as well as of genetic, neuropsychological, and
neuroimaging investigations. They are distinctive disorders identifiable on the basis of a typical age onset, specific
EEG characteristics, seizure types, and often other features which, when taken together, permit a specific diagnosis
which, in turn, often has implications for treatment, management, and prognosis. Each electro-clinical syndrome
can be classified according to age at onset, cognitive and developmental antecedents and consequences, motor
and sensory examinations, EEG features, provoking or triggering factors, and patterns of seizure occurrence with
respect to sleep. Therefore, according to the age at onset, here we review the more frequently observed paediatric
electro-clinical syndrome from their clinical-EEG, genetic and therapeutic point of views.
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Introduction
Syndrome classification is not applicable to all patients
with epilepsy, but only a limited number of patients [1].
In fact, the 1989 syndrome classification assigned, in
each category, “other epilepsies not defined as syn-
dromes”, using, moreover, the terms ‘’syndromes’’ and
‘’epilepsies’’ almost interchangeably. The result was that
the term ‘’syndrome’’ took on a broad and very impre-
cise meaning, to the point where very specific and
highly recognizable entities (such as childhood absence
epilepsy) and poorly differentiated and not well-
described epilepsies (such as cryptogenic parietal lobe
epilepsy), tended to be treated as though they repre-
sented the same level of diagnostic precision.
Moreover, in the past, the term ‘’idiopathic’’ was also
used to convey the idea of a highly pharmaco-responsive
form of epilepsy, whereas, in the new ILAE terminology,
the implication that ‘’idiopathic’’ confers the quality of
‘’benign’’ is, now-days, intentionally discarded. Thus, as
a variety of subtle cognitive and behavioral disorders are
seen in association with idiopathic epilepsies, cause is
no longer equated with prognosis.
In this respect, in fact, at the present time, it might be
reasonable to include some of the traditional electro-
clinical syndromes (ECS) (such as, benign rolandic epi-
lepsy, Panayiotopoulos syndrome, and benign occipital
epilepsy of the Gastaut type), previously classified as
‘’idiopathic’’, in the unknown category [2].
In addition, correlations between genotype and pheno-
type in ECS (table 1) are not so easy to establish, since
genetic and non genetic factors likely play a role in
determining the severity of ECS phenotype. On the
other hand, the numerous and increasing discoveries on
genetic origin are improving our knowledge, and it is
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hoped that this will be useful to define a more targeted
therapeutic approaches for at least some of ECS.
One of the most distinctive and clinically salient
dimensions for classifying ECS is based accordingly to
their typical age at onset, as reported in table 1.
To provide epileptologists a comprehensive highlights
of ECS aspects, among the currently ILAE recognized
ECS (table 1), here we review, from an “electro-clinical”,
therapeutics and genetic points of view, the most fre-
quently observed forms with onset in paediatric age
(table 1).
Early Infantile Epileptic Encephalopathy (EIEE) or
Ohtahara Syndrome (OS)
Early-infantile epileptic encephalopathy, also known as
Ohtahara syndrome [3], is characterized by early onset
of tonic spasms occurring with or without clustering,
seizure intractability, a characteristic interictal bursts-
suppression (SB) pattern (Figure 1) on EEG persistently
observed in both waking and sleeping states and a
remarkable age-dependent evolution into the West syn-
drome (reported in 75% of cases) [4]. Prognosis is very
poor with severe drug-resistance and psychomotor
retardation.
The causes of EIEE are heterogeneous. Several brain
malformations, neuronal migration disorders and meta-
bolic disorders have been found as underlying causes of
symptomatic OS [5]. Two causative genes are thought
to be involved in the pathogenesis of cryptogenic cases
of OS: the aristaless-related homeobox (ARX) and the
syntaxin binding protein 1 (STXBP1) genes. The ARX
gene is considered to have an important role in the neu-
ronal proliferation, in differentiation of the embryonic
brain, and in interneuronal migration, acting as a tran-
scription factor in the development of GABAergic inter-
neurons [6]. Phenotypes associated with ARX mutations
include both malformative and non malformative
syndromes.
Pleiotropic mutations of the ARX gene cause a variety
of phenotypes that are considered to share a common
pathological mechanism related to the structural and
functional disturbance of interneurons, called “inter-
neuronopathies” [7,8]. This hypothesis was supported by
experimental data demonstrating that ARX protein defi-
ciency results in the loss of GABAergic interneurons
and anomalous distribution of residual cells in the cor-
tex and basal ganglia [9]. Consequently, the GABAergic
network dysfunction seems to play a crucial role in the
pathogenesis of SB and in the hypsarrhythmic pattern.
STXBP1, or MUNC18-1 gene encodes syntaxin binding
protein 1, a neuron-specific protein that is essential for
synaptic vesicle release [10,11]. A recent study showed
that mutations in STXBP1 are not limited to patients
with OS, but are also present in patients with an early-
Table 1 Electro-clinical syndromes in paediatric age according to age at onset
A) Neonatal period:
< 44 weeks of gestational age
BFNE
EME
Ohtahara syndrome
B) Infancy:
< 1 year
Epilepsy of infancy with migrating focal seizures
West syndrome
MEI
Benign infantile epilepsy
Benign familial infantile epilepsy
Dravet syndrome
Myoclonic encephalopathy in non progressive disorders
FS+ (can start in childhood)
C) Childhood:
1-12 years
FS+ (can start in infancy)
PS
Epilepsy with myoclonic atonic (previously astatic) seizures
BCECTS
ADNFLE
Late onset childhood occipital epilepsy (Gastaut type)
Epilepsy with myoclonic absences
Lennox-Gastaut syndrome
CSWS
LKS
CAE
D) Adolescence:
12-18 years
JAE
JME
Epilepsy with generalized tonic-clonic seizures alone
Familial focal epilepsy with variable foci (childhood to adult)
Reflex epilepsies
BFNE: Benign familial neonatal epilepsy; EME: Early myoclonic encephalopathy; MEI: Myoclonic epilepsy in infancy; FS+: Febrile seizures plus; PS: Panayiotopoulos
syndrome; BCECTS: Benign epilepsy with centrotemporal spikes; ADNFLE: Autosomal-dominant nocturnal frontal lobe epilepsy; CSWS: Epileptic encephalopathy
with continuous spike-and-wave
during sleep; LKS: Landau-Kleffner syndrome; CAE: Childhood absence epilepsy; JAE: Juvenile absence epilepsy; JME: Juvenile myoclonic epilepsy.
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onset epileptic encephalopathy which do not fit into
either OS or WS. This strongly supports the hypothesis
that mutations in STXBP1 could cause a many kinds of
epileptic disorders [12,13].
Although EIEE is usually characterized by drug resis-
tance, some specific treatments have been reported to
be effective, such as ketogenetic diet [14], liposteroid
administration [15], zonisamide (ZNS) [16], high-dose
phenobarbital (PB) [17], levetiracetam (LEV) [18], and
vigabatrin (GVG) [19]. Selected patients could benefit
from epilepsy surgery [20].
A similar syndrome, Early Myoclonic Encephalopahty
(EME) has an onset within the first few weeks of life.
EME has been associated primarily to metabolic disor-
ders while EIEE is more likely associated to structural
brain abnormalities. This syndrome differs from EIEE
for the main type of clinical seizure observed: EME
patients have fragmentary myoclonus while EIEE
patients have epileptic spasms. EEG in EME shows a
suppression-burst pattern less persistent than the one
seen in EIEE. [3].
Benign Familial Neonatal (BFNS) or Infantile (BFIS) or
Neonatal-Infantile (BFNIS) Seizures
BFNS (also known as Benign Familial Neonatal Convul-
sions) is a rare, monogenic, autosomal-dominant, benign
familial epilepsy syndrome [21]. It is characterized by
unprovoked and brief cluster of focal tonic-clonic con-
vulsions occurring within the first days of life and fre-
quently flowing into status epilepticus. No specific EEG
trait characterizes BFNS: interictal EEG is most com-
monly normal, and if present, anomalies are usually
transient [1,22]. The majority of individuals with BFNS
can be kept seizures-free by using PB. Seizures disappear
spontaneously within 2 months of life. Hovewer, about
10%-15% of children with BFNS develop seizures later
Figure 1 EEG pattern of suppression burst.
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in life with a variable age of onset and duration; in this
eventuality, seizures are mainly generalized tonic or
tonic-clonic seizures, and EEG may be characterized by
centro-temporal spikes and sharp waves or benign epi-
lepsy with centrotemporal spikes [23].
BFNS is linked to mutations in KCNQ2 and KCNQ3
genes [24], which are members of a family of voltage-
gated potassium channel genes (KCNQ1-5). They
encode the voltage-gated Kv7.2 and Kv7.3 channels that
produce a neuronal M-current (muscarinic-regulated
potassium current) which limits the repetitive firing of
many neurons. More than 60 mutations have been
described in BFNS families, with the majority involving
KCNQ2.
No major phenotypic differences are observed between
patients with BFNS caused by a KCNQ2 mutation and
those with BFNS caused by a KCNQ3 mutation. Pene-
trance is incomplete (85%); anticipation has not been
observed [21]. The majority of newborns diagnosed with
BFNS have an affected parent; however, also sporadic
BFNS have been reported. In BFNIS, seizures appear in
neonates, and in BFIS they begin between the 3rd and
the 12th month of life.
Most of children with BFNS can keep seizure free by
using PB (20 mg/kg as loading dose and 5 mg/kg/day as
maintenance dose). In some cases have been used other
anti-epileptic drugs (AEDs) like carbamazepine (CBZ),
phenytoin (PHT), valproic acid (VPA), clonazepam
(CZP), midazolam and GVG. Retigabine, selectively
enhancer of potassium channels, is being tested as an
adjunctive therapy in individuals with partial onset sei-
zures [25]. Treatment is theoretically unnecessary for
BFNIS and BFIS, but as seizures appear in cluster, it
may be necessary to treat them. BFNIS condition could
have some clinical and genetic features overlapping with
BFIS, which is a dominant idiopathic epilepsy with par-
tial and secondarily generalized seizures with age of
onset between 3 and 12 months. Moreover, a mechan-
ism that can explain that epileptic spells in BFNIS occur
almost exclusively during the first days to months of life
has recently been proposed [26]. BFIS is a genetically
heterogenous condition with loci mapped to chromo-
somes 19 and 16. Mutations in the voltage-gated sodium
channel alpha2 subunit (SCN2A) gene on chromosome
2 were recently identified in families affected by neona-
tal and infantile seizures (benign familial neonatal-infan-
tile seizures, BFNIS) with typical onset before 4 months
of life. Striano et al reported a novel SCN2A mutation
in family with benign familial infantile seizures describ-
ing three affected individuals over three generations.
Genetic study in this family revealed a novel heterozy-
gous mutation c.3003 T > A in the SCN2A gene. Com-
parative analysis of different sodium channel alpha
subunits indicates that the mutated residue is highly
conserved throughout the evolution, suggesting an
important functional role for this domain. The identifi-
cation of SCN2A mutations in families with only infan-
tile seizures indicated that BFNIS and BFIS show
overlapping clinical features [27].
West Syndrome and Infantile Spasms
West syndrome (WS), also called Infantile Spasms (IS)
or Salaam Spams/Tics, show an incidence which is esti-
mated about 0,16-0,42 per 1000 live births [28]. In the
first description, it was characterized by a famous triad
that consists of seizures (so-called IS: generally consist-
ing of, sudden, bilaterally and symmetrical, flexor, exten-
sor or mixed type, spasms of the neck, trunk and
extremities), characteristic abnormalities to the electro-
encephalography (hypsarrhytmia) and psychomotor
retardation. The causes of this syndrome are heteroge-
neous and it can be divided in three principal groups:
symptomatic, cryptogenetic and idiopathic. In the symp-
tomatic group the epileptic desease is associated with
various brain damage due to prenatal, perinatal and
postnatal causes.
WS occurs in the first year of life, with a peak age at 5
months, seizures are heterogeneous and occur at awa-
kening and during crying [29].
In 1950 Gastaut and co-workers described the EEG
features associated with WS and then Gibbs and others
conied the term hypsarrhythmia to define an EEG char-
acterized by “random high voltage slow waves and
spikes, that vary from moment to moment in duration
and in location: at the onset, they appear to be focal and
then they seem to originate from multiple foci; in few
cases the spike discharge becomes generalized” [30].
Stromme and Weaving found mutations of two genes,
ARX and STK9, in patients with X-linked familial West
syndrome [31,32]. A polyalanine expansion mutation of
the ARX gene has also been found in a patient with
sporadic cryptogenetic WS [33]. A new STXBP1 muta-
tion on cromosome 9q34.11 in a patients affected by
WS without transition from OS has been reported [34].
Recently, a de novo deletion of 16p13.11 (previously
suggested as risk factor for mental retardation and mul-
tiple congenital anomalies), in a patient with significant
developmental delay, facial dysmorphism and WS, has
been reported [35].
Many new therapeutic options have been tried: GVG,
ZNS, nitrazepam (NZP), methisergide, LEV, topiramate
(TPM), lamotrigine (LTG), pyridoxine, ketogenic diet,
immunoglobulin therapy, felbamate (FLB), and thyrotro-
pin-releasing hormone [36,37]. ACTH is generally esti-
mated to be more effective than corticosteroids and it
appears to positively alter long-term prognosis in the
criptogenetic cases more than in the symptomatic ones
[38].
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GVG has been considered the drugs of first choice for
patients affected by IS associated with tuberous sclerosis,
as well as with Focal Cortical Dysplasia (FCD), and may
also be a second-line agent for the treatment of other
symptomatic IS. The efficacy of GVG is increased with
high doses (100-150 mg/Kg/day) compared with the
standard doses (40-100 mg/Kg/day) [39]. Unfortunately,
GVG- related rethinopathy represents a limit for its use
[40,41]. Brief period and low dose to minimize the prob-
ability of visual field defect GVG related has been sug-
gested [42] and, in case of lack of improvement, GVG
should be discontinued after 12 weeks [43].
Dravet Syndrome (DS) and Genetic Epilepsy with Febrile
Seizure Plus (GEFS+)
GEFS+ is a familial autosomal-dominant epileptic syn-
drome with a large pattern of intra and extrafamilial
phenotypic variability. Patients with GEFS+ may suffer
from febrile seizures (FS) above the 6th year of age
(called febrile seizures plus, FS+) and also afebrile myo-
clonic, absence, atonic, or partial seizures may appear
[44]. FS and FS+ represent the milder form of GEFS+,
whereas “severe myoclonic epilepsy of infancy” (SMEI)
represent the most severe form. SMEI is an epileptic
encephalopathy starting during the first year of life,
especially around the 6th month, with recurrent and
long-lasting febrile seizures, also as febrile status epilep-
ticus. Drug-resistant myoclonic, complex partial, and
atypical absence seizures can appear after the 12
months of life. Hot water seizures and photosensitivity
are present in about 50% of the patients [44]. Regres-
sion of the normally acquired mental capacities may
start from the 2nd year, often related to the episodes of
status epilepticus [44]. Interictal myoclonus, ataxia and
piramidal signs may complete the clinical picture. Japa-
nese authors described patients with uncomplete SMEI
phenotype, and have named these variants as borderline
severe myoclonic epilepsy of infancy (SMEB) and
intractable childhood epilepsy with generalized tonic-
clonic seizures (ICE-GTC) [45,46]. In GEFS+, SMEI,
SMEB, and IGE-GTC mutations in the voltage gated
sodium channel alpha1 subunit (SCN1A) gene have
been discovered. SCN1A gene (Chromosome 2q24.3) is
mainly expressed in the cerebral tissue and is implicated
in generation and propagation of action potentials [47].
About 10% of GEFS+ patients have SCN1A mutation.
In SMEI patients mutations falling in the encoding
exons, which are de novo in 95%, are present in about
80% of cases, and they include missense (39%), non-
sense (22%), frameshift (19%), splice site (10%), genomic
rearrangements (deletions, duplications, amplifications,
translocations) (7%), in-frame deletions (2%), and other
types (silent, complex mutations; 1%) of mutations
[48,49].
Till now, in Dravet syndrome, hundreds of mutations
were found in SCN1A, while only few mutations were
identified in the paralogue gene, SCN2A, which encodes
the alpha2 subunit, that is associated with BFNIS and
BFIS, and other various intractable childhood epilepsies
[50,51]. Mutations of SCN1B gene (voltage-gated
sodium channel beta1 subunit) and GABRG2 gene
(GABA receptor gamma2 subunit) were identified in a
few families with GEFS+ spectrum [52,53].
A number of AEDs such as VPA, clobazam (CLB),
TPM and LEV, are reported to be efficacious in DS
[54,55]; VPA is used as a first-line agent to prevent the
recurrence of febrile seizures and oral/nasal/rectal ben-
zodiazepine is used for any long-lasting seizures, but
these agents are most often insufficient. LTG, CBZ, and
high doses of intravenous PB should be avoided because
they may worsen seizures. TPM, LEV, bromide, and the
ketogenic diet may provide substantial efficacy as
adjunctive therapy/procedure [56]. Chiron reported the
efficacy of stiripentol, a P450 inhibitor, used with VPA
and a benzodiazepine [57]. Alternative therapies such
the ketogenic diet, with controversial results, have been
tried [54,55].
Prolonged treatment with sodium channel-inhibiting
AEDs may aggravate the disease course or lead to severe
refractory status epilepticus [58,59].
Early-Onset Absence Epilepsy (EOAE)
Absence seizures are epileptic manifestations that may
start in children typically between the 4th and the 10th
year of age (Childhood Absence Epilepsy, CAE). Less
commonly, absence seizures may arise before the 4th
year of age (Early-onset Absence Epilepsy), and may be
associated with other neurological disorders (other types
of seizures, developmental delay, and movement disor-
ders) [60]. Recently it has been suggested that Early-
onset pure absence epilepsy (EOAE) is a distinct epi-
lepsy characterized by absences starting from a few
months to 4 years of age, normal early psychomotor
development, good AEDs seizure control and normal
intellectual outcome [61].
Mutations in three different genes have been reported
in children with absence seizures: anomalies of
GABRG2 gene have been described in patients with feb-
rile seizures and CAE [62,63], and mutations in SCN1B
and SCL2A1 genes have been reported in children with
EAOE with [64] or without [65] febrile seizures.
SCL2A1 gene encodes glucose transporter type 1
(GLUT1), a glucose transporter across the blood-brain
barrier; SCL2A1 is responsible for the GLUT1 deficiency
syndrome (infantile-onset epilepsy with heterogeneous
type of seizures, complex movement disorders, ataxia,
intellectual disability, macrocephaly, and hypoglycorrha-
chia) [66], and a large phenotypic spectrum
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characterized by normal glycorrhachia, movement disor-
ders, often normal mental capacities, and seizures, in
particular absence seizures [67]. Starting from these
observation Suls et al. have found mutations in SCL2A1
gene in 12% of a cohort of 34 children with EOAE; the
only clinical feature that can allow to differ children
with EOAE from chidlren with CAE is the earlier age of
onset. In addition, the authors preliminarily reported a
marked reduction of epileptic activity at EEG in two of
the mutated patients receiving ketogenic diet. In fact, it
is of note that ketogenic diet may control seizures in
cases of GLUT1 deficiency syndrome [65]. Lastly, a
recent study performed by the same group of authors
demonstrated that the epileptic phenotypic spectrum of
GLUT1 deficiency is greater than previously recognized.
In fact the authors have reported 12 patients with
SCL2A1 mutations and epilepsy, including absence epi-
lepsies with onset from early childhood to adult life, and
various common forms of Idiopathic Generalized Epi-
lepsy [68].
Recently, mutations in SLC2A1 gene leading to
reduced function of GLUT1, the molecule transporting
glucose across the blood-brain barrier, have been found
in a significant proportion of children with absences
starting before 4 years of age [65]. VPA monotherapy
should represent the first-line treatment because it con-
trols absences in the majority of cases [60,69]. Ethosuxi-
mide (ESM) had been previously used in some patients
with a good seizure control [70]. Benzodiazepines are
also effective to achieve seizure control, but they may
induce tolerance and adverse effects [65,70].
Panayiotopoulos Syndrome
Panayiotopoulos syndrome [PS] is characterised by sei-
zures, often prolonged, with predominantly autonomic
symptoms, and by an EEG that shows shifting and/or
multiple foci, often with occipital predominance” [71].
PS occurs in children who are otherwise normal and,
even after the most severe seizures and autonomic sta-
tus epilepticus, the patient is normal and does not show
any residual neurological or mental abnormalities.
Accordingly, severe case of PS showed the apparent lack
of consequences on the cognitive functions (Full Scale
IQ = 106 at WISC-R) and normal sleep macrostructure
profile in all night polysomnographic recording [72].
Previously considered as occipital epilepsy [73], PS has
recently re-classified as “Autonomic Epilepsy” due to
prominent autonomic manifestation which frequently
represent the main (or sole) ictal epileptic semeiology
[72,74-76].
Generally, age at onset is between 1 and 14 years
(with 13% in the youngest age group of 3-6 years) and
most individuals have their first seizure around the age
of 5 years. This syndrome (affecting males and females
of all races almost equally) is considered the most com-
mon of benign childhood partial seizures after Rolandic
epilepsy.
Unilateral deviation of the eyes with or, rarely, without
ictal vomiting is the commonest ictal manifestation after
emesis, occurring in around two thirds of seizures (60%-
80%). Seizures usually occur during nocturnal sleep, par-
ticularly the early part of sleep, or brief daytime naps. In
nearly all seizures, consciousness is initially intact but
becomes impaired as the seizure progresses, with the
child becoming confused or unresponsive [77]. All func-
tions of the autonomic nervous system can be affected,
such as emesis, pallor, mydriasis, miosis, cardiorespira-
tory and thermoregulatory alterations, incontinence of
urine and/or faeces, hypersalivation and modifications of
intestinal motility; cardiorespiratory arrest and convul-
sive status epilepticus are exceptional [78].
The duration of the seizures is usually longer than 10
min [79]. Approximately half (44%) of them last from
30 min to many hours, developing an autonomic status
epilepticus [75,79]. Interictal EEG shows occipital spikes
(70%) although multifocal spikes with high amplitude
sharp-slow wave complexes at various locations repre-
sent the most common EEG feature. Remarkably, the
clinical manifestations are irrespective of EEG locations
and despite similar clinical manifestations, there is a sig-
nificant EEG variability from normal to abnormal EEG
findings, sometimes in the same patient at different
times. From a genetical point of view there are no avail-
able data, as well as about anticonvulsant therapy due to
sporadic (and often not recognized) occurrence of sei-
zures. Livingston JH et al described 2 families harboring
a novel SCN1A mutation, one of whom had Panayioto-
poulos syndrome and the other a phenotype consistent
with generalized epilepsy with febrile seizures plus. The
author argued that SCN1A mutations may cause sus-
ceptibility to an idiopathic focal epilepsy phenotype, the
final phenotype depending on other (genetic or non
genetic) factors [80]. Martín Del Valle F et al present
two cases of Panayiotopoulos syndrome in two monozy-
gotic twins, without SCN1A alteration, suggesting a
genetic origin, with SCN1A associated with the outcome
but not with the development of this syndrome [81].
As usually there is no need to start with anticonvul-
sant therapy, there are scarce available data about the
efficacy of AEDs. In any case, recently, LEV showed
good results in PS patients [82].
Lennox-Gastaut Syndrome
As regards the etiology, LGS (a rare epileptic encephalo-
pathy comprising generalized slow spikes-waves, mental
deficiency and early onset of multiple and different sei-
zures types) is usually divided into symptomatic or crip-
togenetic group, based on the presence or absence of
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neurological abnormalities or specific causes [83,84].
Symptomatic cases present different causes such as
hypoxic-ischemic encephalopathy, vascular demage,
perinatal meningoencephalitides, tuberous sclerosis,
Down’s Syndrome, trauma, brain tumor and malforma-
tions [83]; in the 10-25% of the patients a previous his-
tory of WS is reported [85].
Usually the onset of LGS is about 8 years of age and
occurrence rates peak between 3 and 5 years. Clinically
the type of seizures are different depending on the
phases of the syndrome; tonic seizures are the most fre-
quent and peculiar type of seizures (tonic axial seizures,
particularly during sleep), but are not necessarily present
at the onset. Tonic refers to “a sustained increase in
muscle contraction lasting a few seconds or minutes”.
The patients can present flexor movement of head and
trunk with apnoea and brief cry associated with abduc-
tion of the limbs, which usually involves the arms; in
others patients the tonic seizures might involve not only
trunkal muscles, and we can observe global tonic attacks
[86]. The second seizure mainly associated with LGS is
atypical absence, characterized by a brief loss of con-
sciousness. Atonic falls or drop attacks are hazardous
and occur in 56% of patients who have slow spike-
waves, but are not diagnostic of LGS [87].
At EEG the characteristic and peculiar abnormalities
are burst of diffuse slow spike-waves at 2-2,5 c/s during
wakefulness, or burst or fast waves and slow polyspikes
and generalized fast activity at about 10 c/s during
sleep; this latter EEG finding is almost pathognomonic
for LGS.
Developmental delay increases with time and the
patients loose cognitive and intellectual skills. The prog-
nosis of these patients is very poor and often their epi-
lepsy remains untreatable [85].
Old AEDs for LGS treatment include benzodiazepine
(CLB, CZP, diazepam (DZP), LZP, NZP), PB, Primidone
(PRM), PHT, VPA, GVG [77]. Benzodiazepine are still
prescribed with the specific risk in LGS of precipitating
tonic status epileptic (TSE) [88]. Though they can con-
trol tonic-clonic seizures, PB and PRM should be
avoided due to cognitive and sedative side effects [89].
PTH can control tonic-clonic seizures and reduce tonic
seizures in LGS, but it can aggravate atypical absences
and myoclonic seizures [84]. More recent therapeutic
options in LGS are FBM, LTG, TPM and RUF [90,91].
FBM was the first to be approved for adjunctive therapy
in LGS and showed a significant effect on “major” sei-
zures. Severe adverse effects appeared a few months
after approval and so, since 1994, FBM was adminis-
tered exclusively for LGS refractory to other AEDs.
Antiepileptic and other drugs used “off-label” in LGS
are acetazolamide (AZM), allopurinol, bromide, flunari-
zine, pyridoxine, ZNS [92].
LGS can occur in association with a variety of specific
malformation of cortical development where Mendelian
inheritance may be observed [93]. The occurrence in
siblings is extremely rare and has been reported in a
family with bilateral frontoparietal polymicrogyria due
to GPR56 mutations [94]. Recently Lawrence et al
reported a novel DXC mutation in a family with three
siblings affected by LGS and anterior pachygyria [95].
Benign childhood epilepsy with centrotemporal spikes
(BCECTS)
Benign childhood epilepsy with centrotemporal spikes
(BCECTS), or benign rolandic epilepsy (BRE), character-
istically starts between 3 and 10 years of age, with a
peak at 7 to 8, and resolves by puberty [96].
BCECTS, are usually brief, unilateral, tonic, clonic, or
tonic-clonic, convulsions involving the face, lips, tongue,
pharyngeal, and laryngeal muscles, with speech arrest,
saliva pooling and drooling without loss of conscious-
ness. The seizures usually occur during sleep and are
sometimes followed by secondary generalization. The
most common inter-ictal EEG features are centro-tem-
poral diphasic or triphasic sharps or spikes occasionally
spreading to the homologous contra-lateral region.
BCECTS usually is associated with “idiopathic” condi-
tions but it has also been reported with brain lesions
such as cortical dysplasia [97]. Few ictal EEG in cases of
rolandic epilepsy have been recorded; in these ceses the
seizures begin with fast rhythms and spikes in the rolan-
dic area that is contralateral to the clinical seizures, with
a progressive increase in amplitude and admixture of
slow waves or polyspikes waves.
Although BCECTS is considered a benign form of
childhood epilepsy that occurs in children who show
normal mental development, recent researches support
the view that children with BCECTS show deficient per-
formance in various neuropsychological areas, without a
definition of a uniform profile [98,99].
On the other hand, the impact of epilepsy on cogni-
tive function is complex, with many variables that can
influence cognitive ability and interact, making it diffi-
cult to determine which factors contribute to the cogni-
tive impairment [100]. In children with rolandic
epilepsy, our group recently clearly indicate [98] an
impairment in selectivity (impulsivity, focused attention,
selective attention, aspects of divided attention) and in
one measure of intensity (arousal) of attention whereas,
the other measure of intensity of attention (vigilance)
showed no impairment. Moreover, deficits of speech-
related abilities seemed to be independent of the effects
of antiepileptic treatment and are reversible after remis-
sion of epilepsy [99].
A strong genetic susceptibility has been suggested in
BCECTS [101,102]. Very recently, a genome-wide study
Parisi et al. Italian Journal of Pediatrics 2011, 37:58
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demonstrated linkage of the centrotemporal sharp wave
EEG trait to 11p13 and several polymorphic markers in
the ELP4 (Elongator Protein Complex 4) gene showed
association with the BCECTS phenotype [103].
In contrast with most canonical forms of BCECTS, a
rare syndrome combining the features of BCECTS and
of speech and language disorders (rolandic epilepsy with
speech dyspraxia, autosomal dominant: RESDAD) has
shown monogenic inheritance [104]. Other families with
monogenic inheritance of a syndrome with clinical fea-
tures reminiscent, if not identical, to RESDAD and
RESDX, have been described more recently [105]. Muta-
tions in SRPX2 (Sushi-Repeat Protein, X-linked 2) cause
rolandic epilepsy with speech impairment (RESDX syn-
drome) or with altered development of the speech cor-
tex (bilateral perisylvian polymicrogyria) [106].
Comorbidity between BCECTS and altered development
of speech motor control (also known as speech sound
disorder) has also been further demonstrated in a recent
case-control study [107]. Another BCECTS-associated
genetic syndrome has been reported in a consangui-
neous family with rolandic epilepsy, paroxysmal exer-
cise-induced dystonia, and writer’s cramp. The
syndrome is inherited as a recessive trait and linkage
was found at 16p12-p11 [108], within the ‘’infantile con-
vulsions and choreoathetosis (ICCA)’’ critical region
[109].
Landau-Kleffner Syndrome
Landau Kleffner (LKS) is a rare syndrome of unknown
etiology (more common in the children between 5 and
7 years af age) which consists mainly of loss of language
skills in children previously normal [110,28]. Language
regression may occur suddenly or in a prolonged period
and aphasia can be primarily receptive or expressive;
probably the language disorder can be defined as a ver-
bal auditory agnosia, that consists of a loss of verbal
comprehension, which may be confused as a acquired
deafness [111]. This aphasia is followed by gradual dete-
rioration also in verbal production and, finally, mutism
and failure to respond to non-verbal sounds [111]. Asso-
ciated with language disorder the children with LKS in
the majority of cases present different types of seizures,
which include episodes of eye blinking or ocular devia-
tion, head drop and minor automatisms with secondary
generalization. In other cases, sizures are focal or tonic-
clonic generalized seizures, typical absences, partial
complex and occasionally myoclonic seizures [112].
Early response to treatment and late outcome in LKS
can be markedly different if the onset is in pre-linguistic
phase (onset under the age of 3-4 years) and these chil-
dren can be misdiagnosed for autistic due to impaired
linguistic skills [113].
EEG shows bilateral temporal spikes or spikes waves,
increasing during sleep. In these patients an awake EEG
usually demonstrates normal background activity and
focal epileptiform abnormalities especially on the tem-
poral lobes; rarely awake EEG can be normal, making
video-NPSG mandatory in these subjects. During the
sleep EEG recording it is observed an activation and dif-
fusion of the epileptic discharges, whereas the pattern of
electrical status epilepticus during sleep (ESES or
CSWS) may often be observed [111]. ESES picture is
characterized by a continuous diffuse spike-waves during
SS [114] (Figure 2) (see criteria definition for ESES in
the next paragraph). ESES or CSWS presence is not
mandatory to make diagnosis of LKS, although it is fre-
quently associated [115].
Clinical seizures control in LKS is easy to obtain much
more than ESES picture remission. Sleep EEG dis-
charges in the majority of patients can persist months
or years causing sometimes severe cognitive impairment,
which can be transient, fluctuant or, rarely, irreversible
with permanent cognitive deficits [100,111].
Among available AEDs, CBZ may cause a worsening
of seizures and it should be avoided. The treatment of
choice in LSK appears to be VPA as mono-therapy or in
combination with a benzodiazepine [28]. Some authors
suggest that steroids and ACTH should be considered
the treatment of choice especially in early onset of dis-
ease [116] with improvement in speech abilities [117]
and EEG anomalies recovery (Figure 3).
CLB, NZP, VPA, ESM and flunitrazepam have been
used with benefits. PB, CBZ, PHT have been reported to
be ineffective or harmful [28]. Language functions and
EEG abnormalities would be influenced significantly by
intravenous immunoglobulin administration [118].
The prognosis of LKS is benign in most cases,
although the improvement of language depends on age
of onset (pre and post-linguistic onset) of the disorder
and the severity of the epileptic seizures. Early onset
makes the prognosis poorer with persistent language dif-
ficulties even in the adult life [112].
There is familial association that suggests a genetic
factor in the development of both the epileptic dis-
charges on EEG and cognitive dysfunction but there is
no direct evidence of genetic predisposition featuring in
LKS etiology [119].
LKS, the continuous spike-and-waves during sleep
syndrome (ESES or CSWSS), and the BCECTS are dif-
ferent entities that are considered as part of a single
continuous spectrum of disorders. Recent reports on the
involvement of the SRPX2 and ELP4 genes with possible
roles in cell motility, migration, and adhesion have pro-
vided first insights into the complex molecular bases of
childhood focal epilepsies [120].
Parisi et al. Italian Journal of Pediatrics 2011, 37:58
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ESES or CSWSS
ESES or CSWS is responsible for less than 1% of the
age-dependent childhood EE, starting generally between
the 5th and 7th year of life [121]. Even if these two terms
are considered synonymous, ESES, firstly described by
Tassinari [122], refers to the EEG pattern (continuous
spike-wave complexes exclusively during non-REM
sleep, with a spike-wave index accounting for at least
80-85% of SS), while CSWS indicates both EEG features
and clinical neuropsychological characteristics of this EE
[122,123]. From a clinical point of view various seizures
type are possible in CSWS affected patient: generalized
tonic-clonic seizures during sleep, atypical absence,
myoclonic and atonic seizures. Developmental delay and
deterioration resulting in a IQ reduction, loss of speech,
behavior and motor involvement (with ataxia, dystonia,
dyspraxia) is often associated [121,123]. In CSWSS may
be present a natural history consisting in three phases:
Figure 2 Neuropolisomnography recording, before oral hydrocortisone administration.
Figure 3 After oral hydrocortisone administration, a complete remission of ESES activity was observed.
Parisi et al. Italian Journal of Pediatrics 2011, 37:58
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initial period with seizures and no developmental invol-
vement (I); intermediate period with seizures, neuropsy-
chological regression and ESES (II); final period with
only neuropsychological deficits (III). However this evo-
lution could be absent, and patients with CSWSS/ESES
may present initially without seizures but “only” with
developmental delay and/or behavior disturbance
[123,124]. In these cases it could be useful to perform a
video-NPSG investigation to deeper study the sleep EEG
along the entire night [100].
A well-known partial epilepsy strongly related to ESES
or CSWSS is the “Atypical Benign Partial Epilepsy of
Infancy and Childhood” (ABPEI) also known as
“Pseudo-Lennox Syndrome”, firstly described by Aicard’
e Chevrie [125]. It was often mistaken, in the past, for
LGS because of the repeated atonic falls, absences and
slow-wave activity at EEG. This form includes general-
ized seizures, atypical absences and atonic-astatic sei-
zures. Axial tonic nocturnal seizures frequently observed
in LGS are never observed in this type. ESES or CSWSS
can be associated with ABPEI or even, in rare cases,
with “Rolandic Epilepsy” [126].
Numerous AEDs have been used for the treatment of
CSWSS, such as LTG, LEV, VPA, steroids, benzodiaze-
pine; among the latter, high doses of DZP have been
used with good results [121]. ESES or CSWSS pictures
may be sometimes particularly refractory to AEDs and
corticosteroid therapy (Figure 2 and 3) or AZM (12-15
mg/Kg/die), in these cases, have shown sometimes good
results [100].
ACTH or hydrocortisone are effective, but side-effects
are well-known. High doses of benzodiazepine (LZP,
NZP) are effective when given in by rapid venous infu-
sion or rectally. The rectal administration of DZP 1 mg/
kg followed by an oral dose of 0.5 mg/kg/die for a per-
iod of 3 weeks gave positive results, with remissions
lasting several months in 9/15 cases of ESES (60%) and
in one typical case of LKF syndrome [125].
There is little evidence to suggest a genetic cause.
Only 1 pair of monozygotic twins with CSWS has been
reported. A family history of seizures, including febrile
convulsions, is found in up to 15% of children with
CSWSS [127]. A recent report of two families character-
ized by coexistent BCECTS and cryptogenic epilepsy
with ESES in first-degree relatives suggest a possible
genetic basis [128].
Late-onset childhood occipital epilepsy (Gastaut type)
Gastaut type-idiopathic childhood occipital epilepsy (G-
ICOE) or idiopathic childhood occipital epilepsy of late
onset is a rare epileptic syndrome often with onset ran-
ging from 3 to 15 years with a mean around 8 years of
age. It is a pure form of idiopathic occipital epilepsy,
included among the idiopathic focal epilepsies in
childhood [1] with an uncertain long-term prognosis
[129]. Seizure are purely occipital, frequent, brief and
diurnal. They comprise simple partial seizures character-
ized by initial visual hallucinations (phosphenes and/or
ictal blindness and illusions); ictal or postictal migraine
headaches occur in half of the patients. Impairment of
consciousness is rare unless associated with hemi-clonic
or generalized convulsions [130]. Interictal EEG record-
ings reveal occipital spike and wave discharges that
attenuate or disappear when the eyes are opened [131].
The prognosis is unclear, although remission occurs in
50-60% of patients within 2-4 years from onset. How-
ever, 40-50% of patients may continue to have visual sei-
zures and infrequent secondary generalized tonic-clonic
seizures, particularly if they have not been appropriately
treated. Rarely, atypical evolutions to epilepsy with con-
tinuous spike-waves during slow wave sleep with cogni-
tive deterioration have been reported [132].
Childhood occipital epilepsy-Gastaut type generally
responds promptly to appropriate treatment with con-
ventional AEDs, such as CBZ and VPA, with seizures
usually remitting within 2-5 years. Verrotti et al. showed
LEV as monohterapy to be effective and well tolerated
[133].
The functional nature of this epilepsy syndrome was
emphasized together with the presence of genetic pre-
disposition in the affected patients. A possible autosomal
dominant pattern for the EEG abnormalities with age
dependent expression and variable penetrance of the sei-
zure disorder has been proposed. Recent studies sug-
gested an association between G-ICOE and idiopathic
generalized epilepsies, suggesting that childhood absence
epilepsy may have a closer genetic relationship to G-
ICOE. There are reports about familial occurrence of G-
ICOE [134].
Jeavons Syndrome (Eyelid Myoclonia with Absences)
Jeavons syndrome (JS) is one of the underreported epi-
leptic syndromes characterized by eyelid myoclonia
(EM), eye closure-induced seizures/electroencephalogra-
phy (EEG) paroxysms, and photosensitivity (Figure 4
and 5). JS has been proposed as idiopathic generalized
epilepsy (IGE) because of normal posterior dominant
background activity and paroxysmal generalized ictal
epileptiform discharges (EDs). The triad of manifesta-
tions are (1) eyelid myoclonia with and without
absences; (2) eye closure-induced seizures and EEG par-
oxysms; and (3) photosensitivity [135].
Eyelid myoclonia, the hallmark of this syndrome,
consists of marked jerking of the eyelids and often
with jerky upward deviation of the eyeballs and the
head (eyelid myoclonia without absences). This may be
associated with or followed by mild impairment of
consciousness (eyelid myoclonia with absences). The
Parisi et al. Italian Journal of Pediatrics 2011, 37:58
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seizures are brief (3 to 6 sec) and occur mainly after
eye closure and consistently many times per day. All
patients are photosensitive. Generalized tonic-clonic
seizures (GTCS), induced by lights or spontaneous, are
probably inevitable in the long term and are particu-
larly provoked by precipitating factors (sleep depriva-
tion, alcohol) and inappropriate AEDs modifications.
Typically, GTCS are sparse and avoidable. Myoclonic
Figure 4 Focal Photosensitive Paroxysmal Response.
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jerks of the limbs may occur but are infrequent and
random. Eyelid myoclonic status epilepticus (1/5 of
patients) consists of repetitive and discontinuous epi-
sodes of eyelid myoclonia with mild absence. Video-
EEG is the most important procedure. It shows fre-
quent and brief (2 to 3 sec) high-amplitude 3 to 6 Hz
generalized spike and wave discharge of mainly poly-
spikes, which generally occur after eye closure. These
are frequently associated with eyelid myoclonia. Photo-
paroxysmal responses occur in all untreated young
patients. VPA, CNZ, ESM, and LEV are treatment
options [135,136].
Figure 5 Generalized Photosensitive Paroxysmal Response.
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Conclusions
There are some ECS with onset in paediatric age which
can be associated with psychomotor development and
cognitive skills deterioration; to prevent neuropsychiatric
impairment, an early recognition can allow us to prop-
erly manage diagnostic flow-charts and appropriate ther-
apeutic options,. Sleep interictal EEG discharges (even
without associated diurnal or nocturnal clinical seizures)
are able to cause transitory or permanent cognitive
impairment, particularly in children with high rate of
inter-ictal spiking. Cognitive functions, mainly under
frontal lobe control, seem to be particularly vulnerable
to epileptic EEG activity during the period of brain
development and maturation. In this respect, from a
physiopathological point of view, the most intriguing
issue is represented by the relationship between ESES
and the pattern of neuropsychological and/or motor
derangement. Moreover, it become easy to understand
how important is to search for new AEDs which will be
able to achieve a better control of both, the clinical sei-
zures and interictal paroxysmal EEG abnormalities, par-
ticularly during sleep.
In other cases, such as in Panayiotopoulos Syndrome,
to avoid over-treatments, it is also crucial to know that
even numerous long lasting “autonomic status epilepti-
cus” episodes, seem to be associated with normal cogni-
tive development. Yet, new advances on clinical natural
course and slight cognitive impairment sometimes asso-
ciated with BCECTS must warn about possible cognitive
impairment in these epileptic children previously con-
sidered not at all at risks.
Finally, the knowledge of specific electro-clinical syn-
drome will help epileptologists to make the right diag-
nostic and therapeutic decisions for treating our
children.
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